Emily Lichtenstein

Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.

K.L., Gray, T.A., Saulino, A. & Collins, F.S. (1991) Interactions of Sp1 with the human c globin promoter: binding and transactivation of normal and mutant promoters. Blood, 78, 1853–1863. Jane, S.M., Gumucio, D.L., Ney, P.A., Cunningham, J.M. & Nienhuis, A.W. (1993) Methylation-enhanced binding of Sp1 to the stage selector element of the human c-globin gene promoter may regulate development specificity of expression. Molecular and Cellular Biology, 13, 3272–3281. Jiang, Z., Luo, H.Y., Huang, S., Farrell, J.J., Davis, L., Th eberge, R., Benson, K., Riolueang, S., Viprakasit, V., Al-Allawi, N.A.S., € Unal, S., G€ umr€ uk, F., Akar, N., Bas ak, A.N., Osorio, L., Badens, C., Pissard, S., Joly, P., Campbell, A.D., Gallagher, P.G., Steinberg, M.H., Forget, B.G. & Chui, D.H.K. (2016) The genetic basis of asymptomatic codon 8 frame-shift (HBB: c.25_26delAA) b-thalassemia homozygotes. British Journal of Haematology, 172, 958–965. Lek, M., Karczewski, K.J., Minikel, E.V., Samocha, K.E., Banks, E., Fennell, T., O’Donnell-Luria, A.H., Ware, J.S., Hill, A.J., Cummings, B.B., Tukiainen, T., Birnbaum, D.P., Kosmicki, J.A., Duncan, L.E., Estrada, K., Zhao, F., Zou, J., Pierce-Hoffman, E., Berghout, J., Cooper, D.N., Deflaux, N., DePristo, M., Do, R., Flannick, J., Fromer, M., Gauthier, L., Goldstein, J., Gupta, N., Howrigan, D., Kiezun, A., Kurki, M.I., Moonshine, A.L., Natarajan, P., Orozco, L., Peloso, G.M., Poplin, R., Rivas, M.A., RuanoRubio, V., Rose, S.A., Ruderfer, D.M., Shakir, K., Stenson, P.D., Stevens, C., Thomas, B.P., Tiao, G., Tusie-Luna, M.T., Weisburd, B., Won, H.H., Yu, D., Altshuler, D.M., Ardissino, D., Boehnke, M., Danesh, J., Donnelly, S., Elosua, R., Florez, J.C., Gabriel, S.B., Getz, G., Glatt, S.J., Hultman, C.M., Kathiresan, S., Laakso, M., McCarroll, S., McCarthy, M.I., McGovern, D., McPherson, R., Neale, B.M., Palotie, A., Purcell, S.M., Saleheen, D., Scharf, J.M., Sklar, P., Sullivan, P.F., Tuomilehto, J., Tsuang, M.T., Watkins, H.C., Wilson, J.G., Daly, M.J. & MacArthur, D.G.; for the Exome Aggregation Consortium (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature, 536, 285–291. Menzel, S., Garner, C., Gut, I., Matsuda, F., Yamaguchi, M., Heath, S., Foglio, M., Zelenika, D., Boland, A., Rooks, H., Best, S., Spector, T.D., Farrall, M., Lathrop, M. & Thein, S.L. (2007) A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nature Genetics, 39, 1197–1199. Ronchi, A., Nicolis, S., Santoro, C. & Ottolenghi, S. (1989) Increased Sp1 binding mediates erythroid-specific overexpression of a mutated (HPFH) c-globin promoter. Nucleic Acids Research, 17, 10231–10234. Sykes, K. & Kaufman, R. (1990) A naturally occurring c-globin gene mutation enhances SP1 binding activity. Molecular and Cellular Biology, 10, 95–102.

Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79

The mutant Myd88L265P protein promotes lymphoma cell survival in diffuse large B-cell lymphoma (DLBCL) by activating NF-κB via Irak-4. On the other hand, constitutively activated signaling of the B-cell receptor (BCR), encoded by CD79A/B , activates NF-κB via Bruton’s tyrosine kinase (Btk).

Updates in Chemotherapy-Induced Nausea and Vomiting: The Oncology Nurse and Oncology Nurse Practitioner's Perspectives

Abstract This CE-certified, web-based activity has been designed to address the educational needs of advanced practice oncology nurse practitioners and oncology nurses who manage patients at risk of developing CINV (online access: www.paradigmmc.com/a408 ). This activity will also be of benefit to other healthcare practitioners interested in the management of patients with CINV. Upon completion of the activity, participants should be better able to evaluate the differences among antiemetic therapies used for the prevention and treatment of CINV; have a better understanding of the clinical trial data for new and emerging antiemetic therapies for the prevention and treatment of CINV; and discuss strategies to educate patients about CINV management and potential side effects of antiemetic therapies.